A more recent study reported that ATM-AVI had potent activity against a large collection of contemporary Enterobacterales isolates (n = 8787; MIC50/90, 0.03/0.12 μg/mL), including MBL-producers (n = 110; MIC50/90, 0.12/0.5 μg/mL), supporting the clinical development of ATM-AVI for the treatment of infections caused by MBL-producing strains (Sader et al., 2021). The gene discussed is ATM; the disease is infection.